Maxim Group analyst Naz Rahman maintained a Buy rating on Aytu BioScience yesterday and set a price target of $7.00.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Naz Rahman has given his Buy rating due to a combination of factors, including Aytu BioScience’s strong financial performance and strategic initiatives. The company reported better-than-expected revenue for F1Q26, with total revenue of $13.9 million, surpassing both consensus and internal estimates. This performance was largely driven by the ADHD franchise, which showed a significant year-over-year growth when adjusted for a one-time rebate benefit.
Furthermore, Aytu’s financial position appears robust, with $32.6 million in cash and equivalents, which is deemed sufficient to support the company’s operations until it achieves cash flow positivity by FY27. The anticipated launch of EXXUA, a treatment for major depressive disorder, in December 2025 is another key factor. Aytu’s strategic focus on this product, along with its established relationships with CNS specialists and psychiatrists, is expected to drive future growth. The company’s plans to target government payers initially and expand to commercial payers later also indicate a well-thought-out market strategy, reinforcing the positive outlook on Aytu’s stock.
According to TipRanks, Rahman is an analyst with an average return of -11.5% and a 32.15% success rate. Rahman covers the Healthcare sector, focusing on stocks such as Silexion Therapeutics, Talphera, and Kazia Therapeutics.
In another report released yesterday, Lake Street also reiterated a Buy rating on the stock with a $8.00 price target.